Literature DB >> 17438046

Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis.

Alison Freifeld, Sandra Arnold, Winnie Ooi, Fabian Chen, Thomas Meyer, L Joseph Wheat, Melinda Smedema, Ann Lemonte, Patricia Connolly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17438046      PMCID： PMC1913267          DOI： 10.1128/AAC.01583-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center.

Authors:  A G Freifeld; P C Iwen; B L Lesiak; R K Gilroy; R B Stevens; A C Kalil
Journal:  Transpl Infect Dis       Date:  2005 Sep-Dec       Impact factor: 2.228

Review 2.  Clinical pharmacokinetics of voriconazole.

Authors:  Dominique Levêque; Yasmine Nivoix; François Jehl; Raoul Herbrecht
Journal:  Int J Antimicrob Agents       Date:  2006-03-24       Impact factor: 5.283

3.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

4.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.

Authors:  S Trifilio; R Ortiz; G Pennick; A Verma; J Pi; V Stosor; T Zembower; J Mehta
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

5.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.

Authors:  Hillard M Lazarus; Jeffrey L Blumer; Saul Yanovich; Haran Schlamm; Alain Romero
Journal:  J Clin Pharmacol       Date:  2002-04       Impact factor: 3.126

7.  Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

Authors:  P Connolly; J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

Authors:  Lynn Purkins; Nolan Wood; Katie Greenhalgh; Michael J Allen; Stuart D Oliver
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

9.  The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.

Authors:  Lynn Purkins; Nolan Wood; Katie Greenhalgh; Malcolm D Eve; Stuart D Oliver; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335
  9 in total
  5 in total

1.  Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.

Authors:  Kelong Han; Robert Bies; Heather Johnson; Blair Capitano; Raman Venkataramanan
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

2.  Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.

Authors:  Dimitra Mitsani; M Hong Nguyen; Ryan K Shields; Yoshiya Toyoda; Eun J Kwak; Fernanda P Silveira; Joseph M Pilewski; Maria M Crespo; Christian Bermudez; Jay K Bhama; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

3.  Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.

Authors:  Kelong Han; B Capitano; R Bies; B A Potoski; S Husain; S Gilbert; D L Paterson; K McCurry; R Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

4.  Voriconazole pharmacokinetics in liver transplant recipients.

Authors:  H J Johnson; Kelong Han; B Capitano; D Blisard; S Husain; P K Linden; A Marcos; E J Kwak; B Potoski; D L Paterson; M Romkes; R Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

5.  Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis.

Authors:  Vaibhav Agrawal; Bryan J Brinda; Sherif S Farag
Journal:  Case Rep Hematol       Date:  2020-02-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.